Profile cover photo
Profile photo
Julia Skripka-Serry
37 followers -
From lab to suit and everything in between
From lab to suit and everything in between

37 followers
About
Julia's posts

Post has attachment
Latest Bioassociate for +Seeking Alpha! Over-Skepticism: 3 Biotech Companies Trading Too Close To Their Cash. $AMBI, $CNAT & $TRGT 

Post has attachment
Check out my latest article for BrainBlogger!

Post has attachment
Latest Bioassociate for +Seeking Alpha! InterMune Is Set To Outperform Its Main Competitor - (pirfenidone vs nintedanib)  http://seekingalpha.com/article/2014931-intermune-is-set-to-outperform-its-main-competitor

Post has attachment

Despite Redhill Biopharma's Complete Response Letter from the FDA for VersaFilm on Feb 3rd, Bioassociate reiterated BUY rating for the company yesterday - http://online.wsj.com/article/PR-CO-20140210-905346.html

Post has attachment
Pharmaceutical companies are dead scared of the current market conditions. 

It would seem that the business of saving lives faced no competition, but now more than ever Big Pharma giants are competing for the same disease niches. Risk is extremely high, and R&D development costs are at the highest level they have ever been. 

This is why the new modus operandi of Pharma is all about friendship and collaboration. 

Check out Bioassociate's 2013 Collaboration and Partnering Review to find out more - http://bio-associate.blogspot.co.il/2014/01/biotech-pharma-2013-licensing.html

Post has attachment
Biotech and Pharma performed well in 2013 - here is Bioassociate's Pharma M&A 2013 review re-briefed in the Israeli Globes [Hebrew] - http://www.globes.co.il/news/article.aspx?did=1000906357

Post has attachment

Post has attachment

Post has attachment
Biotech continues to outperform other sectors, even as venture capital wallets are shrinking. An unprecedented 46 biotech and pharma companies went public this year, in what has become an IPO frenzy of over a decade. For the most part, the newly public companies are developing drugs targeting cancer, infectious disease (especially antibiotic-resistant bacteria) and brain disorders. But some new therapeutic areas which are gaining popularity might surprise you. Check out our latest blog post to find out which diseases are "popular" in the pharma world, and who, so far, are the biggest gainers and losers of this year's IPO craze! - http://bio-associate.blogspot.nl/2013/12/2013-ipo-review-most-popular.html

Post has attachment
Ever wonder which therapeutic area was the most popular for pharma M&A deals in 2013? Now you can know! http://bio-associate.blogspot.nl/2013/12/2013-pharma-m-review-earlier-stage.html
Wait while more posts are being loaded